drugset / Trial / NCT06208072

The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.

NCT06208072

RandomizedParallel-groupOpen-labelDiagnostic

Summary

Despite the available means of treating primary arterial hypertension, the prevalence of hypertensive patients with inadequately controlled blood pressure levels, remains high. The identification of biomarkers with prognostic and predictive roles seems to play an important role in the management of hypertensive patients. Proteomic analysis studies provide encouraging results in the identification of such biomarkers. The goal of this clinical study is to is to highlight peptides through urinary proteomic analysis of obese hypertensive patients, capable of predicting blood pressure response, following treatment with irbesartan or eplerenone.

Timeline

Start
2023-09-01
Primary completion
2024-12-01
Completion
2025-02-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eplerenone Unknown 25 mg Oral
Comparator Irbesartan Small molecule 150 mg Oral